Rhythm Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rhythm Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Rhythm Pharmaceuticals: 23 sponsored US clinical trials, 2 recruiting.
Rhythm Pharmaceuticals sponsors 23 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 8 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypothalamic Obesity, with 3 trials.
Top-decile sponsor footprint
Rhythm Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
NCT06239116
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
NCT05093634
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
NCT06046443
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
NCT04966741
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
NCT05194124
DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
NCT04963231
Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
NCT05046132
Open-Label Study of Setmelanotide in Hypothalamic Obesity
NCT04725240
A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
NCT04348175
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
NCT03746522
Long Term Extension Trial of Setmelanotide
NCT03651765
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
NCT03479437
Setmelanotide in a Single Patient With Partial Lipodystrophy
NCT03262610
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
NCT02896192
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
NCT03013543
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
NCT02849977
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
NCT02311673
Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
NCT02041195
Effects of RM-493 on Energy Expenditure in Obese Individuals
NCT01867437
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
NCT01749137
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Rhythm Pharmaceuticals pipeline
2 recruiting of 23 indexed (9% open); 18 completed (78%).
Phase mix: 8 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Hypothalamic Obesity (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rhythm Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 23 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Rhythm Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Iowa State University · 9% recruiting · 23 trials
- New Approaches to Neuroblastoma Therapy Consortium · 9% recruiting · 23 trials
- Swedish Orphan Biovitrum · 9% recruiting · 23 trials
- University of Nevada, Reno · 9% recruiting · 23 trials
Related
What to do with this Rhythm Pharmaceuticals page
23 registered trials is a research-attention snapshot, not an endorsement of Rhythm Pharmaceuticals or any single study.
- 2 of Rhythm Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypothalamic Obesity is the condition Rhythm Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypothalamic Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rhythm Pharmaceuticals pipeline card: 23 registered trials from official public datasets.Report a data error.